Health Canada Approves Merck’s Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Merck & Co Inc. (MRK) on Thursday said that Health Canada has granted approval of Keytruda as a monotherapy to treat patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours.
:max_bytes(150000):strip_icc():format(jpeg)/INV_SP500Gainers_Losers_2023_GettyImages-1223455297-196b1bea36f64240a70a0ce37ba6d1bc.jpg "Best Times of the Day, Week, and Month to Trade Stocks")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-172751278-cd584128c8ac48bbb99887a942f07eed.jpg "Why the Prices of Sports Tickets Vary So Much")
:max_bytes(150000):strip_icc():format(jpeg)/accountspayable.asp-Final-e4e5efa448a94289b6b17189aa72f10e.jpg "Are Accounts Payable an Expense?")
:max_bytes(150000):strip_icc():format(jpeg)/index-funds-7ae7ad9cf2554db68fa0e8a6e523f41d.jpg "Investing in Index Funds: What You Need to Know")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-175599141-2ce72850981343a9ade6410691182453-17447ba2ff6642b88aa3bbdd53e63f4b.jpg "How Do You Record Adjustments for Accrued Revenue?")